KD025 Shifts Pulmonary Endothelial Cell Bioenergetics and Decreases Baseline Lung Permeability

KD025 is a ROCK2 inhibitor currently being tested in clinical trials for the treatment of fibrotic lung diseases. The therapeutic effects of KD025 are partly due to its inhibition of profibrotic pathways and fat metabolism. However, whether KD025 affects pulmonary microvascular endothelial cell (PMV...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Am J Respir Cell Mol Biol
Autores principales: Lee, Ji Young, Stevens, Reece P., Kash, Mary, Zhou, Chun, Koloteva, Anna, Renema, Phoibe, Paudel, Sunita S., Stevens, Troy
Formato: Artigo
Lenguaje:Inglês
Publicado: American Thoracic Society 2020
Materias:
Original Research
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7528923/
https://ncbi.nlm.nih.gov/pubmed/32628869
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1165/rcmb.2019-0435OC
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares